Humacyte (HUMA) Stock Forecast & Price Target

Compare

1,278 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HUMA Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Humacyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HUMA Stock 12 Month Forecast

Average Price Target

$11.20

▲(372.57%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Humacyte in the last 3 months. The average price target is $11.20 with a high forecast of $25.00 and a low forecast of $4.00. The average price target represents a 372.57% change from the last price of $2.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","26":"$26","6.5":"$6.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,4.341538461538462,6.063076923076923,7.7846153846153845,9.506153846153847,11.227692307692308,12.94923076923077,14.670769230769231,16.392307692307693,18.113846153846154,19.835384615384616,21.556923076923077,23.27846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,3.2800000000000002,3.94,4.6,5.26,5.92,6.58,7.239999999999999,7.8999999999999995,8.559999999999999,9.219999999999999,9.879999999999999,10.54,{"y":11.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,2.726153846153846,2.832307692307692,2.9384615384615387,3.0446153846153847,3.1507692307692308,3.256923076923077,3.363076923076923,3.4692307692307693,3.5753846153846154,3.6815384615384614,3.787692307692308,3.8938461538461535,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$11.20

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh JenningsTD Cowen

TD Cowen

Buy

110.97%

Upside

Reiterated

06/06/25

TD Cowen Reaffirms Their Buy Rating on Humacyte (HUMA)

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

Buy

68.78%

Upside

Initiated

05/15/25

Optimistic Buy Rating for Humacyte Driven by Innovative ATEVs and Promising Market Expansion

Bruce JacksonBenchmark Co.

Benchmark Co.

$17→$14

Buy

490.72%

Upside

Reiterated

05/14/25

Humacyte's Promising Growth: Strong Financials and Successful Symvess Launch Drive Buy Rating

Ryan ZimmermanBTIG

BTIG

Buy

237.55%

Upside

Reiterated

04/17/25

Humacyte's Promising Market Penetration and Revenue Projections Justify Buy Rating

Jason KolbertD. Boral Capital

D. Boral Capital

$25

Buy

954.85%

Upside

Reiterated

03/26/25

Humacyte capital raise brings buying opportunity, says D. Boral CapitalHumacyte capital raise brings buying opportunity, says D. Boral Capital

Allison BratzelPiper Sandler

Piper Sandler

Hold

153.16%

Upside

Assigned

11/14/24

Humacyte (HUMA) Gets a Hold from Piper Sandler

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

Buy

195.36%

Upside

Reiterated

07/01/24

Cantor Fitzgerald Sticks to Its Buy Rating for Humacyte (HUMA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh JenningsTD Cowen

TD Cowen

Buy

110.97%

Upside

Reiterated

06/06/25

TD Cowen Reaffirms Their Buy Rating on Humacyte (HUMA)

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

Buy

68.78%

Upside

Initiated

05/15/25

Optimistic Buy Rating for Humacyte Driven by Innovative ATEVs and Promising Market Expansion

Bruce JacksonBenchmark Co.

Benchmark Co.

$17→$14

Buy

490.72%

Upside

Reiterated

05/14/25

Humacyte's Promising Growth: Strong Financials and Successful Symvess Launch Drive Buy Rating

Ryan ZimmermanBTIG

BTIG

Buy

237.55%

Upside

Reiterated

04/17/25

Humacyte's Promising Market Penetration and Revenue Projections Justify Buy Rating

Jason KolbertD. Boral Capital

D. Boral Capital

$25

Buy

954.85%

Upside

Reiterated

03/26/25

Humacyte capital raise brings buying opportunity, says D. Boral CapitalHumacyte capital raise brings buying opportunity, says D. Boral Capital

Allison BratzelPiper Sandler

Piper Sandler

Hold

153.16%

Upside

Assigned

11/14/24

Humacyte (HUMA) Gets a Hold from Piper Sandler

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

Buy

195.36%

Upside

Reiterated

07/01/24

Cantor Fitzgerald Sticks to Its Buy Rating for Humacyte (HUMA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Humacyte

1 Month

xxx

Success Rate

6/16 ratings generated profit

Average Return

-2.18%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of -2.18% per trade.

3 Months

xxx

Success Rate

10/22 ratings generated profit

Average Return

+5.18%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +5.18% per trade.

1 Year

Ryan ZimmermanBTIG

Success Rate

11/24 ratings generated profit

Average Return

-8.15%

reiterated a buy rating 2 months ago

Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 45.83% of your transactions generating a profit, with an average return of -8.15% per trade.

2 Years

xxx

Success Rate

10/24 ratings generated profit

Average Return

-13.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.67% of your transactions generating a profit, with an average return of -13.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HUMA Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HUMA has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HUMA average Analyst price target in the past 3 months is 11.20.

Each month's total comprises the sum of three months' worth of ratings.

HUMA Financial Forecast

HUMA Earnings Forecast

Next quarter’s earnings estimate for HUMA is -$0.16 with a range of -$0.20 to -$0.14. The previous quarter’s EPS was $0.28. HUMA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year HUMA has Outperformed its overall industry.

HUMA Sales Forecast

Next quarter’s sales forecast for HUMA is $936.00K with a range of $431.00K to $1.84M. The previous quarter’s sales results were $517.00K. HUMA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year HUMA has Preformed in-line its overall industry.

HUMA Stock Forecast FAQ

What is HUMA’s average 12-month price target, according to analysts?

Based on analyst ratings, Humacyte’s 12-month average price target is 11.20.

What is HUMA’s upside potential, based on the analysts’ average price target?

Humacyte has 372.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HUMA a Buy, Sell or Hold?

Humacyte has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Humacyte’s price target?

The average price target for Humacyte is 11.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $4.00. The average price target represents 372.57% Increase from the current price of $2.37.

What do analysts say about Humacyte?

Humacyte’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of HUMA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Humacyte (HUMA) Stock Forecast & Price Target

HUMA Analyst Ratings

HUMA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Humacyte

HUMA Analyst Recommendation Trends

HUMA Financial Forecast

HUMA Earnings Forecast

HUMA Sales Forecast

HUMA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts